Dorsavi Ltd. · ASX:DVL
Dorsavi — Shareholder Meeting (November 2022)
21 slides from Dorsavi's shareholder meeting presentation, Nov 17, 2022
Slide 1: 2022 AGM – Chairman's Address and CEO Presentation
17 November 2022 The Manager, Listings ASX Limited Company Announcements Office Level 4 Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam 2022 Annual General Meeting – Chairman’s Address and CEO Presentation We attach a copy of the Chairman’s address and the CEO’s presentation to be de
Slide 2: Workplace and Clinical
• Workplace: dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company’s cust
Slide 3: Opening Address by Acting Chairman
DORSAVI LTD ANNUAL GENERAL MEETING 17 NOVEMBER 2022 OPENING ADDRESS BY DR MICHAEL PANACCIO, ACTING CHAIRMAN, DORSAVI LTD I appreciate that some shareholders will be disappointed with the Company’s progress over the last few years. Ignoring the impacts of Covid, the last two years have been extremely
Slide 4: AGM CEO Presentation
AGM CEO Presentation November 2022
Slide 5: Leading provider across two major markets
Leading provider across two major markets (clinical and workplace) Unique, validated and proven technology trusted by leading institutions globally Used and validated by leading institutions1 Leading technology Wearable sensors that measure quality of movement and muscle activity in workplace and cl
Slide 6: Robust business model
Robust business model 3
Slide 7: Stable revenue providing a platform for growth
Stable revenue providing a platform for growth Sustained growth with enhanced sales and marketing approach for new product Sales revenue (A$m) $2.4m $2.0m Positive outlook for FY23 underpinned by: $1.9m Focus on recurring revenue has built a stable base from which to grow Enhanced sales and mark
Slide 8: Lean expense management towards a sustainable business
Lean expense management towards a sustainable business Investments made in product and data security for future benefits Operating expenses (A$m)1 Includes ISO27001 certification costs, AMI2 product development and launch costs $6.8m $5.4m $5.1m $5.0m See slide 6 ~$3.0m FY19A FY20A FY21A FY22A FY23F
Slide 9: Further reductions to cost base expected
Further reductions to cost base expected Plan in place to further minimise expenditure with many initiatives already complete Operating expenses bridge (A$m)1 1 1 $5.4m Enhanced sales and customer support model (e.g. remote training and support) ~$1.0m 2 New product driving greater efficiencies
Slide 10: Clear and validated strategy
Clear and validated strategy 7
Slide 11: Clear and validated strategy - valuable target markets
Clear and validated strategy - valuable target markets Targeting two key valuable markets with attractive growth propositions Workplace Clinical Selling sensors direct to physical therapists Contracts with tier one enterprise customers (PT), utilising existing reimbursement codes Use data insi
Slide 12: Workplace market – strategic customers
Workplace market – strategic customers Partnered with insurance companies to reduce premiums and de-risk new client wins QBE strategic relationship Large upside with network effect Strategic relationship with QBE More companies sign Initial relationship with QBE in Australia directly with dorsaVi
Slide 13: Clinical market - direct
Clinical market - direct Provision of digital health tools to physical therapists Over 300 dorsaVi clinical products in the US1 1 14 18 1 2 4 11 8 4 5 Capture novel & clinically Assess the effectiveness of 12 26 21 1 relevant data insights treatment programs 3 18 9 2 10 3 3 16 30 21 11 1 7 16 2 13 9
Slide 14: Upgrades to best-selling Athletic Movement Index (AMI) product
Upgrades to best-selling Athletic Movement Index (AMI) product Technology and product enhancements unlock exciting growth pathways AMI product Features and benefits Product enhancements Assessment time reduced by 50% Superior value proposition ISO 27001 compliant Enhanced functionality and data secu
Slide 15: Multiple growth pathways
Front Plank 25/30 ny ~ ~~ 52/60 R Side Plank R Leg Hop PI y 40/48 7 R Ankle Lunge Multiple growth pathways y dorsaVi 12
Slide 16: Robust clinical market drives revenue growth
Robust clinical market drives revenue growth Revenue growth led by US clinical market Sales revenue (A$m) Revenue growth driven by several factors Clinical market Clinical revenue led by the US +42% The US contributes to over 70% of clinical market revenues $1.6m Use of product is reimbursed Pro
Slide 17: Expanded pipeline of workplace customers
Expanded pipeline of workplace customers Sales pipeline expanded and new deals signed as ‘return-to-work’ momentum continues Value of new workplace contracts won (A$k) +23% Select recent client wins $397k $322k Four new development contracts with Boeing signed, expected to last ~12 months H1 FY22A1
Slide 18: Significant upside potential
Significant upside potential Primed to capitalise on continued return to work and healthcare digitisation trends Return to work with Lean operations with Intelligent increased engagement view to profitability remote care Activities resuming at clinical Reduced operating costs, lower AI based digitis
Slide 19: Important information and disclaimer
Important information and disclaimer Not financial product advice or offer This presentation does not constitute an offer of securities or investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation or particular needs.
Slide 20: Important information and disclaimer
Important information and disclaimer Forward-Looking Statements This document contains or may contain forward-looking statements that are based on dorsaVi management’s beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating p
Slide 21: Contact us
Contact us Company Andrew Ronchi Director and CEO T: +61 417 882 267 E: ar@dorsavi.com Investors Dean Dribbin Vesparum Capital T: +61 3 8582 4800 E: dorsavi@vesparum.com Unit 3, 11-13 Milgate Street South Oakleigh, Vic, 3167 www.dorsavi.com